Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome

Metabolic Syndrome Clinical Trial

Official title:

Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02518854
• Other study ID #: 104-1970A3
• Status: Completed
• Phase: N/A
• First received: August 4, 2015
• Last updated: July 19, 2017
• Start date: June 2015
• Est. completion date: March 31, 2017

Study information

• Verified date: July 2017
• Source: Chang Gung Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Metabolic syndrome (MetS) is highly prevalent all over the world. MetS is largely under-diagnosed in children and adolescents. Obesity and hypertension are two important requirements for criteria of MetS. With early detection and early intervention of MetS in children and adolescents will enable better care to reduce the heavy burden of health care all over the world.

Investigators intend to recruit 150 children and adolescents age 6 to 18 yr with overweight/obesity or prehypertension/hypertension and 50 normal age-matched controls to reach the following research goals:

1) To identify biomarkers as risk factors; 2) To characterize that impact of vascular assessment in preMetS children; and 3) To examine the relationship among biomarkers, vascular assessment parameters, and metabolic phenotypes.

Description:

Metabolic syndrome (MetS) is highly prevalent all over the world, including Taiwan. So far, there is still no standard definition of MetS for use in pediatric population. Thus MetS is largely under-diagnosed in children and adolescents. Obesity and hypertension are two important requirements for criteria of MetS. With early detection and early intervention of MetS in children and adolescents will enable better care to reduce the heavy burden of health care all over the world.

MetS might originate from early life, namely developmental programming. Cardiovascular disease (CVD) is the most common comorbidity of MetS. Therefore identification of biomarkers for detecting children with high-risk to develop CVD and MetS progression is our priority. Investigators' previous studies identified some biomarkers from a variety of programming models, including asymmetric dimethylarginine (ADMA, a nitric oxide synthase inhibitor), β-trace protein (BTP, also known as lipocalin-type prostaglandin D synthase), and adiponectin. Thus, in the current study, ADMA profile, BTP, and adiponectin will be studied in children and adolescents with pre-MetS to explore their role as biomarkers to predict MetS and CVD progression.

In childhood, assessment of CVD relies on endothelial function and arterial stiffness, as CV events are extremely rare. Thus, in this study investigators intend to perform a global vascular assessment (to determine endothelial function and arterial stiffness) in children with pre-MetS including 24hr ABPM, measure of pulse wave velocity (PWV) and ambulatory arterial stiffness index (AASI) to detect arterial stiffness, detection of flow mediated dilatation (FMD), and biomarkers. Investigators also intend to examine the correlation between biomarkers and these measured vascular parameters in children with preMetS.

Therefore, investigators will recruit 150 children and adolescents age 6 to 18 yr with overweight/obesity or prehypertension/hypertension and 50 normal age-matched controls to reach the following research goals:

1) To identify biomarkers as risk factors; 2) To characterize that impact of vascular assessment in preMetS children; and 3) To examine the relationship among biomarkers, vascular assessment parameters, and metabolic phenotypes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: March 31, 2017
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• children with ? one of the following criteria of metabolic syndrome

1. weist circumstance ?90th percentile

2. TG?150 mg/dL

3. HDL<40 mg/dL

4. BP>?90th percentile

5. A.C. glucose>100 mg/dL or T2D

• Volunteer

Exclusion Criteria:

• inability to complete study procedures

• pregnancy

• malignancy.

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Locations

Country	Name	City	State
Taiwan	Kaohsiung Chang Gung Memorial Hospital	Kaohsiung

Sponsors (1)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asymmetric dimethylarginine (ADMA)	Differences of ADMA level (µM) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment
Secondary	Adiponectin	Differences of adiponectin level (µg/mL) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment
Secondary	ß-trace protein (BTP)	Differences of BTP level (mg/dL) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment
Secondary	Flow-mediated dilation (FMD)	Differences of FMD (%) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment
Secondary	Pulse wave velocity (PWV)	Differences of PWV (m/s) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment
Secondary	Ambulatory arterial stiffness index (AASI)	Differences of AASI (unit) in children with pre-Metabolic syndrome vs. control.	At the time of enrollment